RegentAtlantic Capital’s Moderna MRNA Stock Holding History

RegentAtlantic Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.32M	Sell	11,193 -3,136	-22%	-$476K	0.04%	261
2022 Q2	$2.05M	Buy	14,329 +72	+0.5%	+$10.3K	0.07%	209
2022 Q1	$2.46M	Buy	14,257 +3,813	+37%	+$642K	0.07%	199
2021 Q4	$2.65M	Sell	10,444 -3,008	-22%	-$879K	0.07%	183
2021 Q3	$5.18M	Buy	13,452 +12,135	+921%	+$4.48M	0.16%	108
2021 Q2	$309K	Buy	+1,317	New	+$235K	0.01%	523
2021 Q1	–	Sell	-4,946	Closed	-$517K	–	552
2020 Q4	$517K	Sell	4,946 -1,535	-24%	-$155K	0.02%	335
2020 Q3	$459K	Sell	6,481 -2	-0%	-$139	0.02%	337
2020 Q2	$416K	Sell	6,483 -4,054	-38%	-$222K	0.02%	330
2020 Q1	$316K	Sell	10,537 -3,896	-27%	-$89.6K	0.02%	326
2019 Q4	$282K	Sell	14,433 -2,000	-12%	-$35.5K	0.02%	390
2019 Q3	$262K	Sell	16,433 -3,000	-15%	-$44.3K	0.02%	387
2019 Q2	$284K	Buy	+19,433	New	+$417K	0.02%	371

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RegentAtlantic Capital's MRNA Position: Q3 2022 in Review

RegentAtlantic Capital reduced its Moderna (MRNA) stake by 22% in Q3 2022, selling an estimated $476K and leaving 11,193 shares worth $1.32M. The position accounts for 0.04% of the portfolio, ranked #261.

RegentAtlantic Capital first reported a position in MRNA in Q2 2019 and has held it in 13 quarters since. The position peaked at $5.18M in Q3 2021. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

RegentAtlantic Capital held 11,193 shares of Moderna worth $1.32M as of Q3 2022.
RegentAtlantic Capital sold 3,136 Moderna shares in Q3 2022, an estimated $476K.
Moderna made up 0.04% of RegentAtlantic Capital's portfolio in Q3 2022, its #261 holding.
RegentAtlantic Capital first reported a position in Moderna in Q2 2019 and has held it in 13 quarters since.
RegentAtlantic Capital's Moderna position peaked at $5.18M in Q3 2021.
915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.